- Home
- TTNP vs QNRX Comparison
TTNP vs QNRX Comparison
Compare TTNP & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- QNRX
- Stock Information
- Founded
- TTNP 1991
- QNRX 2018
- Country
- TTNP United States
- QNRX United States
- Employees
- TTNP N/A
- QNRX N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- QNRX Medical/Dental Instruments
- Sector
- TTNP Health Care
- QNRX Health Care
- Exchange
- TTNP Nasdaq
- QNRX Nasdaq
- Market Cap
- TTNP 5.4M
- QNRX 4.3M
- IPO Year
- TTNP 1996
- QNRX N/A
- Fundamental
- Price
- TTNP $4.93
- QNRX $7.48
- Analyst Decision
- TTNP
- QNRX
- Analyst Count
- TTNP 0
- QNRX 0
- Target Price
- TTNP N/A
- QNRX N/A
- AVG Volume (30 Days)
- TTNP 49.3K
- QNRX 4.3K
- Earning Date
- TTNP 08-26-2025
- QNRX 08-07-2025
- Dividend Yield
- TTNP N/A
- QNRX N/A
- EPS Growth
- TTNP N/A
- QNRX N/A
- EPS
- TTNP N/A
- QNRX N/A
- Revenue
- TTNP N/A
- QNRX N/A
- Revenue This Year
- TTNP N/A
- QNRX N/A
- Revenue Next Year
- TTNP N/A
- QNRX N/A
- P/E Ratio
- TTNP N/A
- QNRX N/A
- Revenue Growth
- TTNP N/A
- QNRX N/A
- 52 Week Low
- TTNP $3.03
- QNRX $5.01
- 52 Week High
- TTNP $14.80
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- TTNP 62.92
- QNRX 46.09
- Support Level
- TTNP $4.64
- QNRX $7.05
- Resistance Level
- TTNP $5.17
- QNRX $7.80
- Average True Range (ATR)
- TTNP 0.29
- QNRX 0.37
- MACD
- TTNP 0.11
- QNRX 0.04
- Stochastic Oscillator
- TTNP 83.67
- QNRX 51.98
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.